Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy
✍ Scribed by Jue-Yeon Lee; Young-Suk Choi; Jin-Sook Suh; Young-Min Kwon; Victor C. Yang; Seung-Jin Lee; Chong-Pyoung Chung; Yoon-Jeong Park
- Book ID
- 102865260
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- French
- Weight
- 699 KB
- Volume
- 128
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In this study, a cell‐penetrating peptide, the transactivating transcriptional factor (TAT) domain from HIV, was linked to a chitosan/doxorubicin (chitosan/DOX) conjugate to form a chitosan/DOX/TAT hybrid. The synthesized chitosan/DOX/TAT conjugate showed a different intracellular distribution pattern from a conjugate without TAT. Unlike both free DOX and the conjugate without TAT, the chitosan/DOX/TAT conjugate was capable of efficient cell entry. The chitosan/DOX/TAT conjugate was found to be highly cytotoxic, with an IC~50~ value of approximately 480 nM, 2 times less than that of chitosan/DOX (980 nM). The chitosan/DOX/TAT provided decreases in tumor volume of 77.4 and 57.5% compared to free DOX and chitosan/DOX, respectively, in tumor‐bearing mice. Therefore, this study suggests that TAT‐mediated chitosan/DOX conjugate delivery is effective in slowing tumor growth.